Sentry Acquires Emerge Tools to Help Developers Ship Better, Faster Mobile Apps
6.5.2025 15:00:00 CEST | Business Wire | Press Release
Sentry, the leading debugging platform for developers, today announced it has acquired Emerge Tools, a prominent provider of mobile app development solutions. Emerge Tools enables teams to deliver smaller, faster and more reliable mobile apps. Its platform powers visual regression testing at OpenAI and app size monitoring at Spotify. Companies like DoorDash have used Emerge to improve app launch speed by 60%, while Duolingo used Emerge to help delete thousands of lines of unnecessary code.
According to Statista, “mobile applications are projected to generate more than 613 billion dollars in revenue in 2025”. In a fast growing mobile app landscape, slow loading times, excessive battery drain, and UI instability can lead to negative user sentiment and app abandonment. Emerge Tools directly addresses these challenges by giving developers the ability to proactively identify and resolve performance bottlenecks, optimize app size, and maintain a consistent user experience.
“Emerge Tools is a leader in mobile development, with products used by some of the biggest apps in the world,” said Milin Desai, CEO of Sentry. “The rise of AI is reshaping how software is built and shipped and the need for quality tooling has never been greater, especially for mobile. Adding Emerge’s products and team will help Sentry continue to build the best possible platform for mobile developers around the world.”
Sentry, which is well known for error, crash reporting, and tracing tools will integrate Emerge Tools’s product line into their application monitoring platform – creating the most complete mobile app monitoring solution on the market. Companies like Anthropic, Instacart, Lyft, Riot Games, and more than 25,000 other organizations send Sentry over 4 billion mobile events a day. These Sentry customers will now be able to connect the inefficiencies surfaced by Emerge Tools down to the line of code causing lag, long load times, or unresponsive UI elements. All resulting in a smoother and more enjoyable app experience for users.
“We are thrilled to join Sentry and create a world-class mobile experience for developers,” said Josh Cohenzadeh, co-founder and CEO of Emerge Tools. “Together we will help mobile developers on their entire journey, all the way from their first lines of code to shipping to billions of users.”
“We’re especially excited about Sentry’s commitment to developers and Open Source. We look forward to further empowering the mobile community at an even larger scale,” said Noah Martin, co-founder of Emerge Tools. Sentry started the Open Source Pledge, an initiative that promotes Open Source sustainability and the direct funding of FOSS maintainers; Emerge Tools was one of the first companies to take the Pledge.
By leveraging Sentry and Emerge Tools, mobile development teams can:
- Significantly improve app performance and responsiveness.
- Reduce app size, resulting in higher install rates and user satisfaction.
- Enhance UI stability and prevent visual regressions.
- Streamline development workflows and reduce debugging time.
- Deliver superior mobile experiences that drive user engagement and retention.
This is the fourth major acquisition for Sentry, having acquired Specto in November 2021, Codecov in November 2022, and Syntax in April 2023.
Emerge Tools was founded in late 2020 by Josh Cohenzadeh & Noah Martin. They raised funding from Y Combinator, Haystack, Upside Partnership, Liquid 2 Ventures, and Matrix Partners.
About Sentry
Sentry helps every developer detect, understand, and fix broken code, fast. Using Sentry’s debugging platform decreases resolution time from days to minutes, giving developers more time to do the stuff they love, all while making customers happier. Sentry is used by over 4 million developers and 130,000 organizations, including Disney+, Cloudflare, GitHub, Anthropic, Vercel, and Atlassian.
About Emerge Tools
Emerge Tools provides performance and optimization tooling for mobile teams of all sizes. Its suite of products helps developers monitor and improve critical areas like app size, launch performance, visual regressions, and code health. Trusted by companies like OpenAI, Spotify, DoorDash, and Duolingo, Emerge empowers teams to ship high-quality apps.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506505021/en/
Contacts
MEDIA CONTACT
Michael Selvidge
media@sentry.io
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom